A drug for treatment of patients having tinnitus that is accompanied by sudden hearing loss, said drug including neramexane or a pharmaceutically acceptable salt thereof and characterized by the period that patients are affected by tinnitus accompanied by sudden hearing loss being at least 48 months, etc.